Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

Can Doxorubicin Improve Outcomes with Sorafenib Therapy for HCC?

  • Dave Levitan
September 9, 2019
  • Gastrointestinal Cancer, Liver, Gallbladder, and Biliary Tract Cancers

Adding doxorubicin to sorafenib failed to improve overall or progression-free survival over sorafenib alone in patients with advanced hepatocellular cancer (HCC). The study was halted early due to futility.          

Previous laboratory research along with phase I and II trials suggested the combination of doxorubicin and sorafenib could offer improved outcomes in advanced HCC, according to study authors led by Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center in New York. The new phase III CALGB 80802 trial was designed based on those earlier results.          

The new study included a total of 356 patients, randomized to receive either the combination of doxorubicin and sorafenib (180 patients) or sorafenib alone (176 patients); the study was originally planned to include 480 patients, but it was stopped after a futility boundary was crossed at an interim analysis. Results of the study were published online ahead of print on September 5 in JAMA Oncology.          

Baseline demographics were well balanced between the study arms, with a median age of approximately 62 years; more than 85% of both groups were male, and approximately two-thirds of the cohort was white. Approximately 42% of both cohorts had locally advanced disease while 58% had metastatic HCC.          

The median overall survival was 9.3 months with doxorubicin and sorafenib, compared with 9.4 months with sorafenib monotherapy, for a hazard ratio of 1.05 (95% CI, 0.83–1.31; P = 0.68). Progression-free survival was also no different, at 4.0 months with the combination and 3.7 months with monotherapy, for an HR of 0.93 (95% CI, 0.75–1.16; P = 0.54). Time to progression was also similar, at 4.7 months and 4.2 months, respectively (P = 0.49).          

The combination was more toxic than sorafenib alone. Grade 3 or 4 neutropenia occurred in 36.8% of those treated with doxorubicin plus sorafenib, compared with only 0.6% of those treated with sorafenib alone. The same was true for grade 3 or 4 thrombocytopenia, which occurred in 17.5% of those receiving combination therapy and 2.4% of those receiving monotherapy. Grade 3 or 4 cardiac toxic events occurred only in those receiving doxorubicin and sorafenib, with five patients experiencing left ventricular systolic dysfunction (3.0%) and eight experiencing decreased ejection fraction rates (4.8%).          

“The doxorubicin plus sorafenib combination can be added to a long list of phase II treatments in any cancer that were not sustained in phase III trials,” the authors wrote, though they noted that the data from this trial can still be of significant use. “They will help provide insights into a series of correlative research questions that are being studied that will provide data pertinent to patients with HCC.”

Among those questions are an evaluation of radiographic tumor necrosis and its association with treatment response, studies of hepatitis C viral load and its effect on therapy, and others.

“The study is timely considering the continued rising incidence of HCC in the United States and the critical need for better treatments for patients with advanced HCC,” the authors concluded.

Related Articles

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".